WO2016167340A1 - Braf遺伝子変異を有する細胞に対する細胞死誘導剤、当該細胞の増殖抑制剤及び当該細胞の増殖異常に起因する疾患の治療用医薬組成物 - Google Patents
Braf遺伝子変異を有する細胞に対する細胞死誘導剤、当該細胞の増殖抑制剤及び当該細胞の増殖異常に起因する疾患の治療用医薬組成物 Download PDFInfo
- Publication number
- WO2016167340A1 WO2016167340A1 PCT/JP2016/062090 JP2016062090W WO2016167340A1 WO 2016167340 A1 WO2016167340 A1 WO 2016167340A1 JP 2016062090 W JP2016062090 W JP 2016062090W WO 2016167340 A1 WO2016167340 A1 WO 2016167340A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- gst
- cell
- cancer
- mutation
- Prior art date
Links
- 230000030833 cell death Effects 0.000 title claims abstract description 39
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 24
- 230000002159 abnormal effect Effects 0.000 title claims description 16
- 230000002401 inhibitory effect Effects 0.000 title abstract description 16
- 230000000694 effects Effects 0.000 title description 17
- 206010064571 Gene mutation Diseases 0.000 title description 4
- 230000001939 inductive effect Effects 0.000 title description 4
- 230000035755 proliferation Effects 0.000 title 2
- 230000035772 mutation Effects 0.000 claims abstract description 80
- 101150048834 braF gene Proteins 0.000 claims abstract description 72
- 229940079593 drug Drugs 0.000 claims abstract description 44
- 239000003814 drug Substances 0.000 claims abstract description 44
- 239000004480 active ingredient Substances 0.000 claims abstract description 26
- 206010028980 Neoplasm Diseases 0.000 claims description 57
- 201000011510 cancer Diseases 0.000 claims description 50
- 230000010261 cell growth Effects 0.000 claims description 40
- 238000000034 method Methods 0.000 claims description 32
- 230000014509 gene expression Effects 0.000 claims description 29
- 239000003795 chemical substances by application Substances 0.000 claims description 27
- 201000010099 disease Diseases 0.000 claims description 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 27
- 239000000126 substance Substances 0.000 claims description 26
- 229940125431 BRAF inhibitor Drugs 0.000 claims description 22
- 239000000411 inducer Substances 0.000 claims description 21
- 102000039446 nucleic acids Human genes 0.000 claims description 21
- 108020004707 nucleic acids Proteins 0.000 claims description 21
- 150000007523 nucleic acids Chemical class 0.000 claims description 21
- 201000001441 melanoma Diseases 0.000 claims description 20
- 239000003966 growth inhibitor Substances 0.000 claims description 19
- 238000012360 testing method Methods 0.000 claims description 17
- 206010009944 Colon cancer Diseases 0.000 claims description 14
- 239000013598 vector Substances 0.000 claims description 12
- 108020004414 DNA Proteins 0.000 claims description 11
- 230000009368 gene silencing by RNA Effects 0.000 claims description 9
- 108091030071 RNAI Proteins 0.000 claims description 8
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 7
- 108091033319 polynucleotide Proteins 0.000 claims description 7
- 102000040430 polynucleotide Human genes 0.000 claims description 7
- 239000002157 polynucleotide Substances 0.000 claims description 7
- 238000012216 screening Methods 0.000 claims description 7
- 230000000692 anti-sense effect Effects 0.000 claims description 6
- 108090000994 Catalytic RNA Proteins 0.000 claims description 5
- 102000053642 Catalytic RNA Human genes 0.000 claims description 5
- 108091092562 ribozyme Proteins 0.000 claims description 5
- 238000005259 measurement Methods 0.000 claims description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 2
- 230000003247 decreasing effect Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 abstract description 19
- 210000004027 cell Anatomy 0.000 description 151
- 239000004055 small Interfering RNA Substances 0.000 description 39
- 108020004459 Small interfering RNA Proteins 0.000 description 35
- 239000000203 mixture Substances 0.000 description 32
- 239000002609 medium Substances 0.000 description 31
- 108090000623 proteins and genes Proteins 0.000 description 21
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 description 20
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 description 19
- YZDJQTHVDDOVHR-UHFFFAOYSA-N PLX-4720 Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(Cl)=CN=C3NC=2)=C1F YZDJQTHVDDOVHR-UHFFFAOYSA-N 0.000 description 15
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 13
- 239000003112 inhibitor Substances 0.000 description 13
- 235000018102 proteins Nutrition 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 150000001413 amino acids Chemical group 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- 239000012098 Lipofectamine RNAiMAX Substances 0.000 description 9
- 239000012124 Opti-MEM Substances 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 239000000284 extract Substances 0.000 description 9
- 238000011534 incubation Methods 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 238000001890 transfection Methods 0.000 description 9
- 238000001262 western blot Methods 0.000 description 9
- 208000029742 colonic neoplasm Diseases 0.000 description 8
- -1 etc.) Chemical class 0.000 description 8
- 239000003242 anti bacterial agent Substances 0.000 description 7
- 229940088710 antibiotic agent Drugs 0.000 description 7
- 230000006907 apoptotic process Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 description 6
- 230000000903 blocking effect Effects 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 229960003180 glutathione Drugs 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 210000004379 membrane Anatomy 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 239000004033 plastic Substances 0.000 description 6
- 229920003023 plastic Polymers 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- KKVYYGGCHJGEFJ-UHFFFAOYSA-N 1-n-(4-chlorophenyl)-6-methyl-5-n-[3-(7h-purin-6-yl)pyridin-2-yl]isoquinoline-1,5-diamine Chemical compound N=1C=CC2=C(NC=3C(=CC=CN=3)C=3C=4N=CNC=4N=CN=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C=C1 KKVYYGGCHJGEFJ-UHFFFAOYSA-N 0.000 description 5
- 108010024636 Glutathione Proteins 0.000 description 5
- 239000002246 antineoplastic agent Substances 0.000 description 5
- 239000012298 atmosphere Substances 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- DKNUPRMJNUQNHR-UHFFFAOYSA-N 1-[3-(6,7-dimethoxyquinazolin-4-yl)oxyphenyl]-3-[5-(1,1,1-trifluoro-2-methylpropan-2-yl)-1,2-oxazol-3-yl]urea Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1OC(C=1)=CC=CC=1NC(=O)NC=1C=C(C(C)(C)C(F)(F)F)ON=1 DKNUPRMJNUQNHR-UHFFFAOYSA-N 0.000 description 4
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000005720 Glutathione transferase Human genes 0.000 description 4
- 108010070675 Glutathione transferase Proteins 0.000 description 4
- 206010053759 Growth retardation Diseases 0.000 description 4
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 description 4
- YABJJWZLRMPFSI-UHFFFAOYSA-N 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]-2-benzimidazolamine Chemical compound N=1C2=CC(OC=3C=C(N=CC=3)C=3NC(=CN=3)C(F)(F)F)=CC=C2N(C)C=1NC1=CC=C(C(F)(F)F)C=C1 YABJJWZLRMPFSI-UHFFFAOYSA-N 0.000 description 3
- HFYMVDKBZONUOJ-UHFFFAOYSA-N 3-[[4-[1-(2,2-difluoroethyl)-3-(1h-pyrrolo[2,3-b]pyridin-5-yl)pyrazol-4-yl]pyrimidin-2-yl]amino]propanenitrile Chemical compound C=1N=C2NC=CC2=CC=1C1=NN(CC(F)F)C=C1C1=CC=NC(NCCC#N)=N1 HFYMVDKBZONUOJ-UHFFFAOYSA-N 0.000 description 3
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102100030708 GTPase KRas Human genes 0.000 description 3
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 3
- OJFKUJDRGJSAQB-UHFFFAOYSA-N TAK-632 Chemical compound C1=C(NC(=O)CC=2C=C(C=CC=2)C(F)(F)F)C(F)=CC=C1OC(C(=C1S2)C#N)=CC=C1N=C2NC(=O)C1CC1 OJFKUJDRGJSAQB-UHFFFAOYSA-N 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000005907 cancer growth Effects 0.000 description 3
- 210000004748 cultured cell Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- CMJCXYNUCSMDBY-ZDUSSCGKSA-N lgx818 Chemical compound COC(=O)N[C@@H](C)CNC1=NC=CC(C=2C(=NN(C=2)C(C)C)C=2C(=C(NS(C)(=O)=O)C=C(Cl)C=2)F)=N1 CMJCXYNUCSMDBY-ZDUSSCGKSA-N 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- IVDHYUQIDRJSTI-UHFFFAOYSA-N sorafenib tosylate Chemical compound [H+].CC1=CC=C(S([O-])(=O)=O)C=C1.C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 IVDHYUQIDRJSTI-UHFFFAOYSA-N 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- MLSAQOINCGAULQ-QFMPWRQOSA-N (E)-SB-590885 Chemical compound C1=CC(OCCN(C)C)=CC=C1C1=NC(C=2C=CN=CC=2)=C(C=2C=C3CCC(/C3=CC=2)=N\O)N1 MLSAQOINCGAULQ-QFMPWRQOSA-N 0.000 description 2
- XCZIYUDQUDWQHI-UHFFFAOYSA-N 1-[3-(6,7-dimethoxyquinazolin-4-yl)oxyphenyl]-3-[5-(1,1,1-trifluoro-2-methylpropan-2-yl)-1,2-oxazol-3-yl]urea;hydrochloride Chemical compound Cl.C=12C=C(OC)C(OC)=CC2=NC=NC=1OC(C=1)=CC=CC=1NC(=O)NC=1C=C(C(C)(C)C(F)(F)F)ON=1 XCZIYUDQUDWQHI-UHFFFAOYSA-N 0.000 description 2
- HRLQRNBAJCQMMG-UHFFFAOYSA-N 1-n-(4-chlorophenyl)-6-methyl-5-n-[3-(7h-purin-6-yl)pyridin-2-yl]isoquinoline-1,5-diamine;dihydrochloride Chemical compound Cl.Cl.N=1C=CC2=C(NC=3C(=CC=CN=3)C=3C=4NC=NC=4N=CN=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C=C1 HRLQRNBAJCQMMG-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- FSASIHFSFGAIJM-UHFFFAOYSA-N 3-methyladenine Chemical compound CN1C=NC(N)=C2N=CN=C12 FSASIHFSFGAIJM-UHFFFAOYSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 238000009020 BCA Protein Assay Kit Methods 0.000 description 2
- 235000005956 Cosmos caudatus Nutrition 0.000 description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
- WVXNSAVVKYZVOE-UHFFFAOYSA-N DCC-2036 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=C4C=CC=NC4=CC=3)=CC=2)=C1 WVXNSAVVKYZVOE-UHFFFAOYSA-N 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- DEZZLWQELQORIU-RELWKKBWSA-N GDC-0879 Chemical compound N=1N(CCO)C=C(C=2C=C3CCC(/C3=CC=2)=N\O)C=1C1=CC=NC=C1 DEZZLWQELQORIU-RELWKKBWSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 206010069755 K-ras gene mutation Diseases 0.000 description 2
- 101100523539 Mus musculus Raf1 gene Proteins 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 108091007412 Piwi-interacting RNA Proteins 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 2
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 2
- 101710141955 RAF proto-oncogene serine/threonine-protein kinase Proteins 0.000 description 2
- 108091027967 Small hairpin RNA Proteins 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 230000004900 autophagic degradation Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 229960000684 cytarabine Drugs 0.000 description 2
- 229960002465 dabrafenib Drugs 0.000 description 2
- YKGMKSIHIVVYKY-UHFFFAOYSA-N dabrafenib mesylate Chemical compound CS(O)(=O)=O.S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 YKGMKSIHIVVYKY-UHFFFAOYSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 150000002484 inorganic compounds Chemical class 0.000 description 2
- 229910010272 inorganic material Inorganic materials 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 230000002601 intratumoral effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000007914 intraventricular administration Methods 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007721 medicinal effect Effects 0.000 description 2
- 108091070501 miRNA Proteins 0.000 description 2
- 239000002679 microRNA Substances 0.000 description 2
- UMBFDGUGXMOMHX-BQYQJAHWSA-N n-[4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[(e)-2-(4-methoxy-1h-pyrrolo[2,3-b]pyridin-5-yl)ethenyl]-4-methylbenzamide Chemical compound C1CN(CC)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(\C=C\C=2C(=C3C=CNC3=NC=2)OC)=C1 UMBFDGUGXMOMHX-BQYQJAHWSA-N 0.000 description 2
- 239000005445 natural material Substances 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- NAALWFYYHHJEFQ-ZASNTINBSA-N (2s,5r,6r)-6-[[(2r)-2-[[6-[4-[bis(2-hydroxyethyl)sulfamoyl]phenyl]-2-oxo-1h-pyridine-3-carbonyl]amino]-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC(O)=CC=1)C(=O)C(C(N1)=O)=CC=C1C1=CC=C(S(=O)(=O)N(CCO)CCO)C=C1 NAALWFYYHHJEFQ-ZASNTINBSA-N 0.000 description 1
- YYACLQUDUDXAPA-MRXNPFEDSA-N (3r)-n-[3-[5-(2-cyclopropylpyrimidin-5-yl)-1h-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluorophenyl]-3-fluoropyrrolidine-1-sulfonamide Chemical compound C1[C@H](F)CCN1S(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=NC(=NC=2)C2CC2)=C1F YYACLQUDUDXAPA-MRXNPFEDSA-N 0.000 description 1
- MWWSFMDVAYGXBV-FGBSZODSSA-N (7s,9s)-7-[(2r,4s,5r,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydron;chloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-FGBSZODSSA-N 0.000 description 1
- VNTHYLVDGVBPOU-QQYBVWGSSA-N (7s,9s)-9-acetyl-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 VNTHYLVDGVBPOU-QQYBVWGSSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 1
- XDMGVODAJPPESG-UHFFFAOYSA-N 1h-pyrazolo[3,4-b]pyridine-5-carboxamide Chemical class NC(=O)C1=CN=C2NN=CC2=C1 XDMGVODAJPPESG-UHFFFAOYSA-N 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- FJVAQPINJBFBLI-UHFFFAOYSA-N 3-methylquinazolin-4-one Chemical compound C1=CC=C2C(=O)N(C)C=NC2=C1 FJVAQPINJBFBLI-UHFFFAOYSA-N 0.000 description 1
- 238000010600 3H thymidine incorporation assay Methods 0.000 description 1
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- AIRHBAXIGSQPNX-UHFFFAOYSA-N 5-(4-chlorophenyl)-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=CC(Cl)=CC=C1C1=CN=C(NC=C2)C2=C1 AIRHBAXIGSQPNX-UHFFFAOYSA-N 0.000 description 1
- NGFFVZQXSRKHBM-FKBYEOEOSA-N 5-[[(1r,1as,6br)-1-[6-(trifluoromethyl)-1h-benzimidazol-2-yl]-1a,6b-dihydro-1h-cyclopropa[b][1]benzofuran-5-yl]oxy]-3,4-dihydro-1h-1,8-naphthyridin-2-one Chemical compound N1C(=O)CCC2=C1N=CC=C2OC(C=C1[C@@H]23)=CC=C1O[C@@H]3[C@H]2C1=NC2=CC=C(C(F)(F)F)C=C2N1 NGFFVZQXSRKHBM-FKBYEOEOSA-N 0.000 description 1
- RYYCJUAHISIHTL-UHFFFAOYSA-N 5-azaorotic acid Chemical compound OC(=O)C1=NC(=O)NC(=O)N1 RYYCJUAHISIHTL-UHFFFAOYSA-N 0.000 description 1
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 1
- KABRXLINDSPGDF-UHFFFAOYSA-N 7-bromoisoquinoline Chemical compound C1=CN=CC2=CC(Br)=CC=C21 KABRXLINDSPGDF-UHFFFAOYSA-N 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 108090000672 Annexin A5 Proteins 0.000 description 1
- 102000004121 Annexin A5 Human genes 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 1
- 206010061825 Duodenal neoplasm Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- SAMRUMKYXPVKPA-VFKOLLTISA-N Enocitabine Chemical compound O=C1N=C(NC(=O)CCCCCCCCCCCCCCCCCCCCC)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 SAMRUMKYXPVKPA-VFKOLLTISA-N 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- ZPLQIPFOCGIIHV-UHFFFAOYSA-N Gimeracil Chemical compound OC1=CC(=O)C(Cl)=CN1 ZPLQIPFOCGIIHV-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100030943 Glutathione S-transferase P Human genes 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101001010139 Homo sapiens Glutathione S-transferase P Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101000964453 Homo sapiens Zinc finger protein 354C Proteins 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 101150105104 Kras gene Proteins 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
- 239000002138 L01XE21 - Regorafenib Substances 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 1
- 208000032271 Malignant tumor of penis Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000015021 Meningeal Neoplasms Diseases 0.000 description 1
- 101100381978 Mus musculus Braf gene Proteins 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- 241001425800 Pipa Species 0.000 description 1
- KMSKQZKKOZQFFG-HSUXVGOQSA-N Pirarubicin Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1CCCCO1 KMSKQZKKOZQFFG-HSUXVGOQSA-N 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- AHHFEZNOXOZZQA-ZEBDFXRSSA-N Ranimustine Chemical compound CO[C@H]1O[C@H](CNC(=O)N(CCCl)N=O)[C@@H](O)[C@H](O)[C@H]1O AHHFEZNOXOZZQA-ZEBDFXRSSA-N 0.000 description 1
- 108091060570 RasiRNA Proteins 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 101000744436 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Trans-acting factor D Proteins 0.000 description 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010054184 Small intestine carcinoma Diseases 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- WFWLQNSHRPWKFK-UHFFFAOYSA-N Tegafur Chemical compound O=C1NC(=O)C(F)=CN1C1OCCC1 WFWLQNSHRPWKFK-UHFFFAOYSA-N 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- IWEQQRMGNVVKQW-OQKDUQJOSA-N Toremifene citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 IWEQQRMGNVVKQW-OQKDUQJOSA-N 0.000 description 1
- 102000007238 Transferrin Receptors Human genes 0.000 description 1
- 108010033576 Transferrin Receptors Proteins 0.000 description 1
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 1
- 208000023915 Ureteral Neoplasms Diseases 0.000 description 1
- 206010046392 Ureteric cancer Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 102000012088 Vasoactive Intestinal Peptide Receptors Human genes 0.000 description 1
- 108010075974 Vasoactive Intestinal Peptide Receptors Proteins 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
- 102100040311 Zinc finger protein 354C Human genes 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012822 autophagy inhibitor Substances 0.000 description 1
- GRHLMSBCOPRFNA-UHFFFAOYSA-M azanide 2-oxidoacetate platinum(4+) Chemical compound N[Pt]1(N)OCC(=O)O1 GRHLMSBCOPRFNA-UHFFFAOYSA-M 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- YAYRGNWWLMLWJE-UHFFFAOYSA-L carboplatin Chemical compound O=C1O[Pt](N)(N)OC(=O)C11CCC1 YAYRGNWWLMLWJE-UHFFFAOYSA-L 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013601 cosmid vector Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229960002448 dasatinib Drugs 0.000 description 1
- 229960003334 daunorubicin citrate Drugs 0.000 description 1
- 229960003109 daunorubicin hydrochloride Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229960002918 doxorubicin hydrochloride Drugs 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 201000000312 duodenum cancer Diseases 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 229950011487 enocitabine Drugs 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 229960003265 epirubicin hydrochloride Drugs 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- ADFOJJHRTBFFOF-RBRWEJTLSA-N estramustine phosphate Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)OP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 ADFOJJHRTBFFOF-RBRWEJTLSA-N 0.000 description 1
- 229960004750 estramustine phosphate Drugs 0.000 description 1
- AVOLMBLBETYQHX-UHFFFAOYSA-N etacrynic acid Chemical compound CCC(=C)C(=O)C1=CC=C(OCC(O)=O)C(Cl)=C1Cl AVOLMBLBETYQHX-UHFFFAOYSA-N 0.000 description 1
- 229960003199 etacrynic acid Drugs 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 208000024519 eye neoplasm Diseases 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- 102000006815 folate receptor Human genes 0.000 description 1
- 108020005243 folate receptor Proteins 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005144 gemcitabine hydrochloride Drugs 0.000 description 1
- 229950009822 gimeracil Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000009546 growth abnormality Effects 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 101150008380 gstp1 gene Proteins 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 229960000443 hydrochloric acid Drugs 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 229960001176 idarubicin hydrochloride Drugs 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229960000779 irinotecan hydrochloride Drugs 0.000 description 1
- GURKHSYORGJETM-WAQYZQTGSA-N irinotecan hydrochloride (anhydrous) Chemical compound Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 GURKHSYORGJETM-WAQYZQTGSA-N 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 208000012804 lymphangiosarcoma Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 208000022006 malignant tumor of meninges Diseases 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 239000013586 microbial product Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 1
- 229960004169 mitoxantrone hydrochloride Drugs 0.000 description 1
- DPCXEUSDRQOOGZ-QLYXXIJNSA-N n,n-dimethyl-2-[4-[(4z)-4-(1-nitroso-2,3-dihydroinden-5-ylidene)-5-(1h-pyridin-4-ylidene)-1h-imidazol-2-yl]phenoxy]ethanamine Chemical compound C1=CC(OCCN(C)C)=CC=C1C(NC1=C2C=CNC=C2)=N\C1=C\1C=C2CCC(N=O)=C2C=C/1 DPCXEUSDRQOOGZ-QLYXXIJNSA-N 0.000 description 1
- SUNCACOTKLUNHD-UHFFFAOYSA-N n-[2,4-difluoro-3-(5-pyridin-3-yl-1h-pyrrolo[2,3-b]pyridine-3-carbonyl)phenyl]propane-2-sulfonamide Chemical compound CC(C)S(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=NC=CC=2)=C1F SUNCACOTKLUNHD-UHFFFAOYSA-N 0.000 description 1
- JSKJFDXTKYWPAH-UHFFFAOYSA-N n-[2-chloro-3-(1-cyclopropyl-8-methoxy-2h-pyrazolo[3,4-c]isoquinolin-7-yl)-4-fluorophenyl]-3-fluoropropane-1-sulfonamide Chemical compound COC1=CC=2C3=C(C4CC4)NN=C3N=CC=2C=C1C1=C(F)C=CC(NS(=O)(=O)CCCF)=C1Cl JSKJFDXTKYWPAH-UHFFFAOYSA-N 0.000 description 1
- VLLGHDRJSXCFJL-UHFFFAOYSA-N n-thiophen-2-ylbenzamide Chemical class C=1C=CC=CC=1C(=O)NC1=CC=CS1 VLLGHDRJSXCFJL-UHFFFAOYSA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 229950007221 nedaplatin Drugs 0.000 description 1
- 229960001420 nimustine Drugs 0.000 description 1
- VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 201000008106 ocular cancer Diseases 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 229950000193 oteracil Drugs 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229960001221 pirarubicin Drugs 0.000 description 1
- 201000002511 pituitary cancer Diseases 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 150000003057 platinum Chemical class 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229960002185 ranimustine Drugs 0.000 description 1
- 102000016914 ras Proteins Human genes 0.000 description 1
- 229950007043 rebastinib Drugs 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 229960004836 regorafenib Drugs 0.000 description 1
- FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 229960000487 sorafenib tosylate Drugs 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000003699 striated muscle Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- FQZYTYWMLGAPFJ-OQKDUQJOSA-N tamoxifen citrate Chemical compound [H+].[H+].[H+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 FQZYTYWMLGAPFJ-OQKDUQJOSA-N 0.000 description 1
- 229960003454 tamoxifen citrate Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229960001674 tegafur Drugs 0.000 description 1
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000007979 thiazole derivatives Chemical class 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 229960004167 toremifene citrate Drugs 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 238000013042 tunel staining Methods 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229960003862 vemurafenib Drugs 0.000 description 1
- KDQAABAKXDWYSZ-PNYVAJAMSA-N vinblastine sulfate Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 KDQAABAKXDWYSZ-PNYVAJAMSA-N 0.000 description 1
- 229960004982 vinblastine sulfate Drugs 0.000 description 1
- AQTQHPDCURKLKT-JKDPCDLQSA-N vincristine sulfate Chemical compound OS(O)(=O)=O.C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 AQTQHPDCURKLKT-JKDPCDLQSA-N 0.000 description 1
- 229960002110 vincristine sulfate Drugs 0.000 description 1
- 229960005212 vindesine sulfate Drugs 0.000 description 1
- 229960002166 vinorelbine tartrate Drugs 0.000 description 1
- GBABOYUKABKIAF-IWWDSPBFSA-N vinorelbinetartrate Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC(C23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IWWDSPBFSA-N 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
- G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y205/00—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5)
- C12Y205/01—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5) transferring alkyl or aryl groups, other than methyl groups (2.5.1)
- C12Y205/01018—Glutathione transferase (2.5.1.18)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Definitions
- the present invention relates to a cell death inducer for a cell having a BRAF gene mutation (for example, a kind of cancer cell), a growth inhibitor of the cell, and a pharmaceutical composition for treating a disease caused by abnormal growth of the cell,
- the present invention relates to a method for screening a death inducer and / or a cytostatic agent.
- the BRAF gene is a gene encoding one of serine threonine kinases constituting the RAS-RAF-MAPK pathway.
- BRAF gene mutations have been reported in various tumors. For example, a mutation (V600E) in which 600th valine is substituted with glutamic acid is observed in many cancer cells. BRAF with the V600E mutation is known to always activate downstream signals, leading to cell proliferation without stimulation from outside the cell.
- the BRAF gene having the V600E mutation has been observed in many colorectal cancers (5-15%) and melanoma (about 60%). In many cancers such as pancreatic cancer and colon cancer, mutations in the KRAS gene are frequently observed.
- KRAS protein is a G protein localized inside the cell membrane.
- RAS such as KRAS activates RAF such as CRAF and BRAF, RAF continues to form MEK, and MEK activates MAPK (Non-Patent Documents 1 and 2). Cases having both BRAF mutation and KRAS mutation are rare and are in a relationship of BRAF mutation and KRAS mutation mutual exclusion (Non-patent Document 3).
- GST glutathione-S-transferase
- GST glutathione-S-transferase
- GST is classified into six types of isozymes of ⁇ , ⁇ , ⁇ , ⁇ , ⁇ , and ⁇ as representatives based on the amino acid sequence.
- GST- ⁇ also called glutathioneathS-transferase pi or GSTP1
- GSTP1 glutathioneathS-transferase pi
- Non-Patent Documents 4 to 6 reports that when an androgen-independent prostate cancer cell line overexpressing GST- ⁇ is allowed to act on siRNA for GST- ⁇ , its growth is suppressed and apoptosis is increased.
- GST- ⁇ forms a complex with c-Jun N-terminal kinase (JNK) and inhibits JNK activity (Non-patent Document 8). Furthermore, GST- ⁇ is known to be involved in S-glutathionization of proteins related to the stress response of cells (Non-patent Document 9). Furthermore, GST- ⁇ is known to contribute to the protective action against cell death induced by reactive oxygen species (ROS) (Non-patent Document 10). Thus, it can be understood that GST- ⁇ has various features and functions among GSTs.
- ROS reactive oxygen species
- Patent Document 11 discloses that apoptosis of cancer cells can be induced by using a drug that suppresses GST- ⁇ and an autophagy inhibitor such as 3-methyladenine as active ingredients. Further, Patent Document 2 discloses that inhibition of expression of GST- ⁇ and Akt and the like simultaneously suppresses cell proliferation and induces cell death, and autophagy induced by inhibition of GST- ⁇ expression includes Akt. It is disclosed that it is remarkably suppressed by simultaneously inhibiting the expression of and the like.
- the present invention provides an agent having a cell death-inducing action and / or a cell growth-inhibiting action on cells having a mutation in the BRAF gene, and a pharmaceutical composition for treating a disease caused by abnormal cell growth. It is an object of the present invention to provide a method for screening a cell death inducer and / or a cell growth inhibitor.
- a cell death inducer for cells having a mutation in the BRAF gene which contains a drug that suppresses GST- ⁇ as an active ingredient.
- a cell growth inhibitor for cells having a mutation in the BRAF gene which contains a drug that suppresses GST- ⁇ as an active ingredient.
- the drug is a substance selected from the group consisting of RNAi molecules, ribozymes, antisense nucleic acids, DNA / RNA chimeric polynucleotides, and vectors expressing at least one of these (1) ) Or (2).
- a pharmaceutical composition for treating a disease caused by abnormal growth of cells having a mutation in the BRAF gene comprising the agent according to any one of (1) to (6) above.
- a screening method for a cell death inducer and / or a cell growth inhibitor of a cell having a mutation in BRAF gene comprising selecting a drug that suppresses GST- ⁇ .
- the cell death inducer according to the present invention can induce cell death very strongly against cells having a mutation in the BRAF gene. Therefore, the cell death inducer according to the present invention can exhibit a very high medicinal effect as a pharmaceutical composition for the treatment of diseases caused by abnormal growth of cells having a mutation in the BRAF gene.
- the cell growth inhibitor according to the present invention can be suppressed very strongly against cells having a mutation in the BRAF gene. Therefore, the cell growth inhibitor according to the present invention can exhibit a very high medicinal effect as a pharmaceutical composition for the treatment of diseases caused by abnormal growth of cells having a mutation in the BRAF gene.
- the screening method of the present invention it is possible to select a drug that induces cell death and / or suppresses cell proliferation very strongly against cells having a mutation in the BRAF gene.
- the cell death inducer and cell growth inhibitor according to the present invention contain a drug that suppresses GST- ⁇ as an active ingredient.
- the cell death inducer and cell growth inhibitor according to the present invention exhibit a cell death inducing effect and a cell growth inhibiting effect on cells having a mutation in the BRAF gene.
- GST- ⁇ refers to an enzyme that catalyzes glutathione conjugation encoded by the GSTP1 gene.
- GST- ⁇ exists in various animals including humans, and its sequence information is also known (for example, human: NM_000852 (NP_000843), rat: NM_012577 (NP_036709), mouse: NM_013541 (NP_038569), etc.)
- the numbers are NCBI databases.
- the accession number of the base sequence is shown outside the parentheses, and the amino acid sequence number is shown in parentheses).
- nucleotide sequence of the coding region of the human GST- ⁇ gene registered in the database is shown in SEQ ID NO: 1
- amino acid sequence of the human GST- ⁇ protein encoded by the human GST- ⁇ gene is shown in SEQ ID NO: 2.
- GST- ⁇ can be specified by a specific base sequence and amino acid sequence, but the possibility of base sequence and amino acid sequence variations between individual organisms (including polymorphisms) must be considered. I must. That is, GST- ⁇ is not limited to a protein having the same sequence as the amino acid sequence registered in the database, and one or more, typically one or several, for example 1 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acids have different sequences, including those having functions equivalent to GST- ⁇ .
- GST- ⁇ comprises a base sequence having 70% or more, 80% or more, 90% or more, 95% or more, or 97% or more identity to the specific base sequence described above, and GST- ⁇ It also includes those that encode proteins with equivalent functions.
- the specific function of GST- ⁇ means an enzyme activity that catalyzes glutathione conjugation as described above.
- the “drug that suppresses GST- ⁇ ” used in the present specification is not limited, and includes, for example, a drug that suppresses production and / or activity of GST- ⁇ , and degradation and / or inactivation of GST- ⁇ .
- Drugs that promote Examples of drugs that suppress GST- ⁇ production include, but are not limited to, RNAi molecules, ribozymes, antisense nucleic acids, DNA / RNA chimeric polynucleotides for DNA encoding GST- ⁇ , and these. A vector etc. are mentioned.
- any compound that acts on GST- ⁇ can be used as a drug that suppresses GST- ⁇ .
- organic compounds amino acids, polypeptides or derivatives thereof, low molecular compounds, sugars, high molecular compounds, etc.
- inorganic compounds, and the like can be used as a drug that suppresses GST- ⁇ .
- Such a compound may be a natural substance or a non-natural substance.
- polypeptide derivatives include modified polypeptides obtained by adding modifying groups, variant polypeptides obtained by altering amino acid residues, and the like.
- such compounds may be single compounds, but compound libraries, gene library expression products, cell extracts, cell culture supernatants, fermentative microbial products, marine organism extracts, plant extracts A thing etc. may be sufficient. That is, the “drug that suppresses GST- ⁇ ” is not limited to nucleic acids such as RNAi molecules, and includes any compound.
- the drug that suppresses the activity of GST- ⁇ is not limited to this, but for example, a substance that binds to GST- ⁇ , such as glutathione, glutathione analog (for example, WO 95/08563, WO 96/40205, WO 99/54346, as described in Non-Patent Document 4, etc.), ketoprofen (Non-Patent Document 2), indomethacin (Hall et al., Cancer Res. 1989; 49 (22): 6265-8) , Ethacrynic acid, pyroprost (Tew et al., Cancer Res. 1988; 48 (13): 3622-5), anti-GST- ⁇ antibody, dominant negative mutant of GST- ⁇ , and the like.
- these drugs are commercially available or can be appropriately produced based on known techniques.
- Drugs that suppress GST- ⁇ production or activity include RNAi molecules, ribozymes, antisense nucleic acids, DNA / RNA chimeras for DNA encoding GST- ⁇ due to its high specificity and low possibility of side effects. Polynucleotides and vectors expressing them are preferred.
- the inhibition of GST- ⁇ can be determined by the fact that the expression and activity of GST- ⁇ are suppressed in the cells as compared with the case where no GST- ⁇ inhibitor was allowed to act.
- the expression of GST- ⁇ is not limited to any known method, for example, immunoprecipitation using an anti-GST- ⁇ antibody, EIA, ELISA, IRA, IRMA, Western blotting, immunohistochemistry, immunization Cytochemistry, flow cytometry, various nucleic acids using nucleic acids that specifically hybridize to a nucleic acid encoding GST- ⁇ or a unique fragment thereof or a transcription product (eg, mRNA) or splicing product of the nucleic acid. It can be evaluated by a hybridization method, Northern blot method, Southern blot method, various PCR methods and the like.
- the activity of GST- ⁇ is not limited to the known activity of GST- ⁇ .
- it binds to proteins such as Raf-1 (particularly phosphorylated Raf-1) and EGFR (particularly phosphorylated EGFR).
- the sex and the like can be evaluated by analyzing by any known method such as immunoprecipitation, Western blotting, mass spectrometry, pull-down, surface plasmon resonance (SPR), and the like.
- an RNAi molecule refers to any molecule that causes RNA interference, including, but not limited to, siRNA (small interfering RNA), miRNA (micro RNA), shRNA (short hairpin RNA), ddRNA (DNA- directed (RNA), piRNA (Piwi-interacting RNA), double-stranded RNA such as rasiRNA (repeat associated ⁇ siRNA), and variants thereof.
- siRNA small interfering RNA
- miRNA miRNA
- micro RNA miRNA
- shRNA short hairpin RNA
- ddRNA DNA- directed (RNA)
- piRNA piRNA
- double-stranded RNA such as rasiRNA (repeat associated ⁇ siRNA)
- antisense nucleic acid includes RNA, DNA, PNA, or a composite thereof.
- a DNA / RNA chimeric polynucleotide is not limited, for example, a double-stranded polynucleotide comprising DNA and RNA that inhibits expression of a target gene described in JP-A-2003-219893. Including.
- the compounding amount of the active ingredient in the agent or composition of the present invention may be an amount that induces cell death such as apoptosis and / or suppresses cell proliferation when the agent or composition is administered.
- an amount that does not cause adverse effects exceeding the benefits of administration is preferred.
- Such an amount is known or can be appropriately determined by an in vitro test using cultured cells or a model animal such as a mouse, rat, dog or pig. Such a test method is well known to those skilled in the art.
- Induction of apoptosis is evaluated by various known methods such as DNA fragmentation, binding of annexin V to the cell membrane, changes in mitochondrial membrane potential, caspase activation and other phenomena specific to apoptosis, and TUNEL staining.
- the amount of the active ingredient may vary depending on the dosage form of the agent or the composition. For example, when a composition of a plurality of units is used for one administration, the amount of the active ingredient blended in one unit of the composition may be a plurality of the amount of the active ingredient necessary for one administration. it can. Those skilled in the art can appropriately adjust the blending amount.
- a cell death inducer, a cell growth inhibitor, a cell death inducer composition or a cell growth inhibitory composition can be produced by blending a drug that suppresses GST- ⁇ as an active ingredient.
- a drug that suppresses GST- ⁇ which is used for cell death induction or cell growth suppression. Furthermore, it is possible to provide a method for inducing cell death or a method for suppressing cell proliferation, which comprises administering an effective amount of a drug that suppresses GST- ⁇ .
- any of the above-described cell death induction or cell growth suppression methods such as apoptosis may be an in-vitro method or an in-vivo method.
- the drug in the method is as described above, and the effective amount of the drug may be an amount that induces cell death or suppresses cell proliferation in the administered cell.
- an amount that does not cause adverse effects exceeding the benefits of administration is preferred.
- Such an amount is known or can be appropriately determined by an in vitro test using cultured cells or the like, and such a test method is well known to those skilled in the art.
- Induction of cell death or suppression of cell proliferation can be evaluated by various known techniques including those described above.
- the effective amount may not necessarily cause cell death or growth suppression to all cells of the cell population when the drug is administered to a predetermined cancer cell population.
- the effective amount is 1% or more, 2% or more, 3% or more, 4% or more, 5% or more, 6% or more, 8% or more, 10% or more, 12% or more of the cells in the cell population, 15% % Or more, 20% or more, or even 25% or more may be an amount that causes apoptosis or growth inhibition.
- the cell death inducer and cell growth inhibitor according to the present invention act on cells having a mutation in the BRAF gene.
- a cell having a mutation in the BRAF gene is a cell (typically a cancer cell) that exhibits a growth abnormality due to the mutation in the BRAF gene.
- the cell death inducer and cell growth inhibitor according to the present invention are cells that highly express GST- ⁇ among cells exhibiting abnormal growth due to mutations in the BRAF gene (typically GST- ⁇ is increased). It is preferable to apply to cancer cells that express.
- cancer cells that highly express GST- ⁇ are cells in which the BRAF gene has a mutation and shows abnormal cell proliferation, and the expression level of GST- ⁇ is significantly higher than normal cells. Means.
- the expression level of GST- ⁇ can be measured according to a conventional method such as RT-PCR or microarray.
- the mutation in the BRAF gene means a mutation such as deletion, substitution, addition or insertion in the amino acid sequence of the wild type BRAF, or a mutation in the expression control region of the BRAF gene.
- the mutation in the BRAF gene is a so-called gain-of-function mutation (gain of function). That is, a BRAF gene having a mutation (sometimes referred to as a mutant BRAF gene) includes a gene encoding a mutant BRAF whose serine-threonine kinase activity is enhanced due to the mutation.
- Mutant BRAF genes also include those in which the expression control region contains a mutation and the expression level is increased compared to the wild type BRAF gene. That is, a cell expressing a mutant BRAF gene has a characteristic that a downstream signal from BRAF (for example, a signal to MEK) is constantly maintained by expressing the mutant BRAF or increasing the expression level of BRAF. Have.
- the mutant BRAF gene includes a gene encoding a mutant BRAF in which valine encoded by codon 600 in the wild-type BRAF gene is replaced with glutamic acid (denoted as V600E, the same applies hereinafter), V600D, V600G, V600K, V600M, V600R V600L, G469A, G469V, D594N, V600insT (insertion of T), and the like.
- V600E glutamic acid
- the cell death inducer or cell growth inhibitor of the present invention can effectively induce cell death or suppress cell proliferation even in cancer cells having mutations in the BRAF gene, cancer cells having mutations in the BRAF gene It is effective as a component of a pharmaceutical composition for a disease caused by abnormal growth of cerevisiae.
- a pharmaceutical composition for diseases caused by abnormal growth of cancer cells having a mutation in the BRAF gene can be produced by blending a drug that suppresses GST- ⁇ as an active ingredient.
- it is possible to treat / treat diseases caused by abnormal cell proliferation including administering an effective amount of the produced pharmaceutical composition to a subject in need thereof.
- the pharmaceutical composition is effective for treating diseases caused by abnormal growth of cancer cells having a mutation in the BRAF gene.
- diseases caused by cancer cells having mutations in the BRAF gene include, but are not limited to, cancers that highly express GST- ⁇ , and in many cases, cancers having mutations in the BRAF gene are GST Included in cancers that highly express - ⁇ .
- fibrosarcoma malignant fibrous histiocytoma, liposarcoma, rhabdomyosarcoma, leiomyosarcoma, hemangiosarcoma, Kaposi sarcoma, lymphangiosarcoma, synovial sarcoma, chondrosarcoma, Sarcomas such as osteosarcoma, eye cancer, thyroid cancer (papillary cancer), meningeal cancer, brain tumor, pituitary cancer, salivary gland cancer, head and neck cancer, breast cancer, lung cancer (non-small cell cancer), esophageal cancer, gastric cancer, duodenal cancer , Appendic cancer, colon cancer, rectal cancer, liver cancer, pancreatic cancer, gallbladder cancer, bile duct cancer, anal cancer, renal cancer, ureteral cancer, bladder cancer, prostate cancer, penile cancer, testicular cancer, uterine cancer (endometrial cancer) Cancers
- cancer includes epithelial malignant tumors and non-epithelial malignant tumors.
- the cancer in the present invention may be any part of the body, for example, brain, head and neck, chest, limbs, lung, heart, thymus, esophagus, stomach, small intestine (duodenum, jejunum, ileum), large intestine (colon, cecum, appendix).
- liver pancreas, gallbladder, anus, kidney, ureter, bladder, prostate, penis, testis, uterus, ovary, vulva, vagina, skin, striated muscle, smooth muscle, synovium, cartilage, bone, thyroid , Adrenal glands, peritoneum, mesentery, bone marrow, blood, vascular system, lymph nodes such as lymph nodes, lymph fluid and the like.
- the cell death inducer or cell growth inhibitor of the present invention can effectively induce cell death even among cells having a mutation in the BRAF gene and having acquired resistance to the BRAF inhibitor, or Cell proliferation can be suppressed. Therefore, the cell death inducer or cell growth inhibitor of the present invention is a pharmaceutical composition for a disease caused by abnormal growth of cancer cells having a mutation in the BRAF gene and having resistance to a BRAF inhibitor. It is effective as a component of In addition, a pharmaceutical agent for a disease caused by abnormal growth of a cancer cell having a mutation in the BRAF gene and having resistance to a BRAF inhibitor by combining a drug that suppresses GST- ⁇ as an active ingredient A composition can be produced. Furthermore, treatment and treatment of diseases caused by abnormal cell proliferation, including administering an effective amount of the produced pharmaceutical composition to a subject in need thereof, that is, a patient with reduced therapeutic effect by a BRAF inhibitor can do.
- a BRAF inhibitor specifically inhibits signal transduction caused by a substance that inhibits signal transduction downstream from BRAF, particularly, mutant BRAF having the above-described gain-of-function mutation (gain of function). It means to include substances.
- BRAF inhibitors include Vemurafenib (PLX4032), Cas ⁇ No .: 918504-65-1, N- [3- [5- (4-chlorophenyl) -1H-pyrrolo [2,3-b] pyridine.
- BRAF inhibitors include regorafenib, dasatinib, PLX-8394, BeiGene-283, PLX-3603, RG-7304 (CAS NO.: 213406-50-9), LY-3009120 (CAS NO .: 1454682 -72-4), rebastinib (Cas.No .: 1020172-07-9), 1H-pyrazolo [3,4-b] pyridine-5-carboxamide analog, ASN-003, Vemurafenib prodrug, N- ( thiophen-2-yl) benzamide derivatives, DCB-R0237, REDX-04988, EBI-907, EBI-945, gossipin, nanolipole-007, TEW-0201, miRNA-3157 and thiazole derivatives (NMS-P186, NMS-P285, NMS-P349, NMS-P383, NMS-P396 and NMS-P730).
- BRAF inhibitors include SB590885 (Cas (No .: 405554-55-4, N, N-dimethyl-2- [4-[(4Z) -4- (1-nitroso-2,3 -dihydroinden-5-ylidene) -5- (1H-pyridin-4-ylidene) -1H-imidazol-2-yl] phenoxy] ethanamine), B-Raf inhibitor 1 (Cas No .: 1093100-40-3, 1 -N- (4-chlorophenyl) -6-methyl-5-N- [3- (7H-purin-6-yl) pyridin-2-yl] isoquinoline-1,5-diamine), B-Raf inhibitor 1 dihydrochloride (Cas No .: 1191385-19-9, 1-N- (4-chlorophenyl) -6-methyl-5-N- [3- (7H-purin-6-yl) pyridin-2-yl] iso
- the pharmaceutical composition according to the present invention may be used in combination with other active ingredients in addition to the drug that suppresses GST- ⁇ .
- the combined use includes, for example, administration of other active ingredients as separate preparations, and administration of other active ingredients as a combination with at least one other drug.
- preparations containing other active ingredients may be administered before other preparations, simultaneously with other preparations, or after other preparations.
- the BRAF inhibitor described above can be used as appropriate.
- Other active ingredients include those that are effective in treating the target disease.
- an anticancer agent can be used in combination.
- anticancer agents include, for example, alkylating agents such as ifosfamide, nimustine hydrochloride, cyclophosphamide, dacarbazine, melphalan, ranimustine, gemcitabine hydrochloride, enocitabine, cytarabine ocphosphat, cytarabine formulation, tegafur uracil, tegafur Gimeracil / oteracil potassium combination drug (eg TS-1), antimetabolite such as doxyfluridine, hydroxycarbamide, fluorouracil, methotrexate, mercaptopurine, idarubicin hydrochloride, epirubicin hydrochloride, daunorubicin hydrochloride, daunor
- platinum complexes such as carboplatin, cisplatin (CDDP) and nedaplatin
- angiogenesis inhibitors such as thalidomide, neobasstat and bevacizumab, and L-asparaginase.
- the active ingredient in the various agents, compositions, treatment methods, etc. of the present invention described in the present specification is a nucleic acid such as an RNAi molecule, a ribozyme, an antisense nucleic acid, a DNA / RNA chimeric polynucleotide, etc.
- a nucleic acid such as an RNAi molecule, a ribozyme, an antisense nucleic acid, a DNA / RNA chimeric polynucleotide, etc.
- the vector any known vector such as a plasmid vector, a phage vector, a phagemid vector, a cosmid vector, or a virus vector can be used.
- the vector preferably includes at least a promoter that enhances the expression of the nucleic acid carried, and in this case, the nucleic acid is preferably operably linked to such a promoter.
- Nucleic acid operably linked to a promoter means that the nucleic acid and the promoter are arranged so that the protein encoded by the nucleic acid is appropriately produced by the action of the promoter.
- the vector may or may not be replicable in the host cell, and transcription of the gene may be performed outside or inside the nucleus of the host cell. In the latter case, the nucleic acid may be integrated into the genome of the host cell.
- the active ingredient can be supported on various non-viral lipids or protein carriers.
- examples of such carriers include, but are not limited to, cholesterol, liposomes, antibody protomers, cyclodextrin nanoparticles, fusion peptides, aptamers, biodegradable polylactic acid copolymers, polymers, and the like, and increase the efficiency of incorporation into cells.
- cationic liposomes and polymers for example, polyethyleneimine
- polymers useful as such carriers include those described in US ⁇ ⁇ ⁇ 2008/0207553, US 2008/0312174, and the like.
- the active ingredient may be combined with other optional ingredients as long as the effect of the active ingredient is not hindered.
- optional components include other chemotherapeutic agents, pharmacologically acceptable carriers, excipients, diluents and the like.
- the composition may be coated with an appropriate material such as an enteric coating or a time-disintegrating material. It may be incorporated.
- compositions of the present invention described herein can be produced by various routes including both oral and parenteral, such as, without limitation, oral, intravenous, Intramuscular, subcutaneous, topical, intratumoral, rectal, intraarterial, intraportal, intraventricular, transmucosal, transdermal, intranasal, intraperitoneal, intrapulmonary, intrauterine, etc. It may be formulated into a dosage form suitable for the administration route. Any known dosage form and formulation method can be adopted as appropriate (see, for example, Standard Pharmaceutical Sciences, Yoshiaki Watanabe, Nankodo, 2003, etc.).
- dosage forms suitable for oral administration include, but are not limited to, powders, granules, tablets, capsules, solutions, suspensions, emulsions, gels, syrups, etc.
- Suitable dosage forms include injections such as solution injections, suspension injections, emulsion injections, and injections prepared at the time of use.
- Formulations for parenteral administration can be in the form of aqueous or non-aqueous isotonic sterile solutions or suspensions.
- the various agents or compositions (including various pharmaceutical compositions) of the present invention described in the present specification may be targeted to specific tissues or cells. Targeting can be accomplished by any known technique. When intended for delivery to cancer, without limitation, for example, the formulation is passive by making the diameter 50 to 200 nm, particularly 75 to 150 nm, etc. suitable for the expression of enhanced Epermability (permeability and retention) effect. Targeting, CD19, HER2, transferrin receptor, folate receptor, VIP receptor, EGFR (Torchilin, AAPS J.
- RAAG10 (Special Table 2005-532050), PIPA (Special Table 2006-506071), ligands such as KID3 (special table 2007-529197), peptides having RGD motif or NGR motif, F3, LyP-1 (Ruoslahti et al., J Cell Biol. 2010; 188 (6): 759-68) can be used as a targeting agent.
- ligands such as KID3 (special table 2007-529197), peptides having RGD motif or NGR motif, F3, LyP-1 (Ruoslahti et al., J Cell Biol. 2010; 188 (6): 759-68) can be used as a targeting agent.
- carriers containing retinoids as targeting agents can also be used. In addition to the above-mentioned documents, such carriers are described in WO 2009/036368, WO ⁇ ⁇ 2010/014117, WO ⁇ ⁇ 2012/170952, and the like.
- compositions of the present invention may be supplied in any form, but from the viewpoint of storage stability, for example, a form that can be prepared at the time of use, for example, Alternatively, it may be provided in a form that can be prepared by a doctor and / or pharmacist, nurse, or other paramedical at or near a medical site. Such a form is particularly useful when the agent or composition of the present invention contains components that are difficult to stably store, such as lipids, proteins, and nucleic acids.
- the agent or composition of the present invention is provided as one or more containers containing at least one of the essential components thereof, and is used prior to use, for example, within 24 hours, preferably 3 Prepared within an hour and more preferably immediately before use.
- reagents, solvents, dispensing devices and the like that are usually available at the place of preparation can be appropriately used.
- the present invention provides a preparation kit for a composition
- a preparation kit for a composition comprising one or two or more containers containing active ingredients that can be contained in various agents or compositions of the present invention alone or in combination, and such a kit.
- the necessary components of various agents or compositions provided in the form of may contain instructions describing how to prepare and administer the various agents or compositions of the present invention, such as instructions, electronic recording media such as CDs and DVDs, and the like. Good.
- the kit of this invention may contain all the components for completing the various agents or compositions of this invention, it does not necessarily need to contain all the components. Therefore, the kit of the present invention may not contain reagents and solvents that are usually available at medical sites, experimental facilities, etc., such as sterile water, physiological saline, and glucose solution.
- the effective amount in the various treatment methods of the present invention described in the present specification is, for example, an amount that reduces the symptoms of the disease or delays or stops the progression of the disease, preferably suppresses the disease, or The amount to heal.
- an amount that does not cause adverse effects exceeding the benefits of administration is preferred.
- Such an amount can be appropriately determined by an in vitro test using cultured cells or the like and a test in a model animal such as a mouse, rat, dog or pig, and such a test method is well known to those skilled in the art. .
- the dose of the drug used in the treatment method of the present invention is known to those skilled in the art, or can be appropriately determined by the above-described test or the like.
- the specific dose of active ingredient administered in the treatment methods of the invention described herein can vary depending on various conditions related to the subject in need of treatment, such as severity of symptoms, general health status of the subject, age, weight It can be determined in consideration of the subject's sex, diet, timing and frequency of administration, medications used in combination, responsiveness to treatment, dosage form, and compliance with treatment.
- Administration routes include various routes including both oral and parenteral, such as oral, intravenous, intramuscular, subcutaneous, topical, intratumoral, rectal, intraarterial, intraportal, intraventricular, transmucosal, Routes such as transdermal, intranasal, intraperitoneal, intrapulmonary, and intrauterine are included.
- the frequency of administration varies depending on the properties of the agent and composition used and the conditions of the subject including the above, but for example, many times a day (ie, 2, 3, 4 or 5 times a day), 1 day a day Times, every few days (ie every 2, 3, 4, 5, 6, 7 days, etc.), every week, every few weeks (ie every 2, 3, 4 weeks, etc.).
- the term “subject” means any living individual, preferably an animal, more preferably a mammal, more preferably a human individual.
- a subject may be healthy or suffer from some disease, but when treatment of a specific disease is intended, typically the subject is suffering from such disease.
- treatment also encompasses all types of medically acceptable prophylactic and / or therapeutic interventions intended to cure, temporarily ameliorate or prevent disease, etc. Shall.
- treatment encompasses medically acceptable interventions for various purposes, including delaying or stopping the progression of disease, regression or disappearance of lesions, preventing onset or preventing recurrence, and the like.
- a drug that suppresses GST- ⁇ exhibits cell death induction and / or cell growth suppression for cells having a mutation in the BRAF gene. Therefore, cell death inducers and / or cell growth inhibitors for cells having mutations in the BRAF gene can be screened using inhibition of GST- ⁇ as an index. That is, a substance capable of suppressing GST- ⁇ is a candidate substance for a cell death inducer and / or cell growth inhibitor of a cell having a mutation in the BRAF gene (typically a cancer cell).
- a test substance is brought into contact with a cancer cell having a mutation in the BRAF gene, and the expression level of GST- ⁇ in the cell is measured. If the expression level when contacting the test substance decreases compared to the expression level measured in the absence of the test substance, the test substance is selected as a drug candidate substance that suppresses GST- ⁇ . can do.
- test substance is not limited at all, and any substance may be used.
- the test substance may be a single substance or a mixture composed of a plurality of components.
- the test substance may be configured to include an unidentified substance such as an extract from a microorganism or a culture solution, or may be configured to include a known composition at a predetermined composition ratio. May be.
- the test substance may be any of protein, nucleic acid, lipid, polysaccharide, organic compound and inorganic compound.
- Example 1 the cell growth inhibitory effect when a drug that suppresses GST- ⁇ was allowed to act on cells having a mutation in the BRAF gene was examined.
- cancer cells having a mutation (V600E) in the BRAF gene 37 types of colon cancer cell lines (CACO-2) and 4 types of melanoma cell lines (A375, SK-MEL-28, A2058, Malme-3M) The cells were cultured at 5 ° C. in an atmosphere containing 5% CO 2 .
- the media used were CACO-2 for MEM + 20%, FBS + 0.1 mM and NEAA, A375 for DMEM + 15% and FBS, SK-MEL-28 for EMEM + 10% and FBS, A2058 for DMEM + 10% and FBS, Malme-3M was IMDM + 20% and FBS, and antibiotics were added to both.
- each cell was seeded on a 100 mm tissue culture plastic dish using an antibiotic-free medium so as to be 10-20% confluent.
- Opti-MEM I Reduced Serum Medium (GIBCO)
- 600 pmol of GST- ⁇ siRNA GGGAGGCAAGACCUUCAUUTT, siRNA ID # 2385, Ambion (SEQ ID NO: 3)
- 35 ⁇ L of Lipofectamine RNAi MAX (Invitrogen) was diluted in 1 mL of Opti-MEM I Reduced Serum Medium (GIBCO) and mixed gently.
- the diluted GST- ⁇ siRNA and the diluted Lipofectamine RNAi MAX were gently mixed and then incubated at room temperature for 10 minutes. During this time, the medium was replaced with 10 mL of Opti-MEM I Reduced Serum Medium. After 10 minutes incubation, the complex of GST- ⁇ siRNA and Lipofectamine RNAi MAX was added to the cells and incubated at 37 ° C. in an atmosphere containing 5% CO 2 . After 5 hours of incubation, the medium was replaced with 10 mL of antibiotic-free medium. One hour after the medium exchange, the cells were washed with PBS, detached with 0.25% Trypsin-EDTA (SIGMA), and suspended in a medium containing antibiotics.
- SIGMA Trypsin-EDTA
- the cells were suspended in 5 ml medium and seeded on a 60 mm tissue culture plastic dish (CACO-2: 0.4 ⁇ 10 5 cells, A375: 1.0 ⁇ 10 5 cells, SK-MEL-28: 0.2 ⁇ 10 5 cells, A2058: 0.8 ⁇ 10 5 pieces, Malme-3M: 0.6 ⁇ 10 5 pieces).
- the expression of GST- ⁇ when GST- ⁇ siRNA was allowed to act on CACO-2 cells, A375 cells, SK-MEL-28 cells, A2058 cells and Malme-3M cells was determined by Western blotting. Respectively. That is, Western blot analysis of GST- ⁇ knockdown was performed using cells collected 3 days after transfection with GST- ⁇ siRNA. First, after washing the collected cells with cold PBS, cold lysis buffer (1% NP-40, 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, complete Mini EDTA-free (Roche), PhosSTOP (Roche) was added, and the mixture was solubilized by ice cooling and incubation for 30 minutes.
- cold lysis buffer 1% NP-40, 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, complete Mini EDTA-free (Roche), PhosSTOP (Roche) was added, and the mixture was solubil
- the mixture was reacted with an anti-GST- ⁇ antibody (MBL) diluted with Membrane® blocking® Solution (Invitrogen) at 4 ° C. for 16 hours.
- the secondary antibody reaction was performed at room temperature for 1 hour using a horseradish peroxidase (HRP) -labeled rabbit antibody.
- HRP horseradish peroxidase
- Band signal detection was performed on an X-ray film by chemiluminescence using ECL Western Blocking Detection Reagents (GE Healthcare). Washing between each operation was carried out 4 times with PBS-T for 5 minutes.
- FIG. 1 The results regarding the colorectal cancer cell line are shown in FIG. 1, and the results regarding the melanoma cell line are shown in FIG.
- FIG.1 and 2 the result of having measured the number of cells and the result of the analysis by a Western blot are shown collectively.
- GST- ⁇ knockdown by GST- ⁇ siRNA a drug that suppresses GST- ⁇ , is used in cancer cells having a BRAF gene mutation in both colorectal cancer cell lines and melanoma cell lines. As a result, cell proliferation ability was remarkably suppressed.
- a mutation in the BRAF gene has been observed in highly malignant tumors, and is known as a poor prognosis factor in unresectable colorectal cancer in colorectal cancer.
- Half of melanoma patients have a mutation in the BRAF gene, and when the metastatic potential is high, the mortality and malignancy are the highest. From the results of this Example, it was suggested that a drug that suppresses GST- ⁇ is effective in suppressing cell proliferation for cancers having mutations in such BRAF gene. Therefore, a novel therapeutic method for these intractable cancers Is expected to lead to
- Example 2 the cell growth inhibitory effect when a drug that inhibits GST- ⁇ and a BRAF inhibitor were allowed to act on cells having mutations in the BRAF gene was examined.
- Example 2 In the same manner as in Example 1, one type of colon cancer cell line (CACO-2) and two types of melanoma cell lines (SK-MEL-28 and A2058) were cultured, and 10-20% confluent the day before transfection. In a 100 mm tissue culture plastic dish using an antibiotic-free medium. In 1 mL of Opti-MEM I Reduced Serum Medium (GIBCO), 600 pmol of GST- ⁇ siRNA (GGGAGGCAAGACCUUCAUUTT, siRNA ID # 2385, Ambion (SEQ ID NO: 3)) was added and mixed gently.
- GIBCO Opti-MEM I Reduced Serum Medium
- RNAi MAX (Invitrogen) was diluted in 1 mL of Opti-MEM I Reduced Serum Medium (GIBCO) and mixed gently. The diluted GST- ⁇ siRNA and the diluted Lipofectamine RNAi MAX were gently mixed and then incubated at room temperature for 10 minutes. During this time, the medium was replaced with 10 mL of Opti-MEM I Reduced Serum Medium. After 10 minutes incubation, the complex of GST- ⁇ siRNA and Lipofectamine RNAi MAX was added to the cells and incubated at 37 ° C. in an atmosphere containing 5% CO 2 . After 5 hours of incubation, the medium was replaced with 10 mL of antibiotic-free medium.
- the BRAF inhibitor PLX4720 (Selleck) is 40 ⁇ M for CACO-2, 0.7 ⁇ M for SK-MEL-28, and 10 ⁇ M for A2058. In the medium, the culture was continued until day 5.
- the control of PLX4720 treatment was performed by adding DMSO (Wako Pure Chemical) as a solvent. Growth assay was performed by counting the number of cells from day 0 to day 5 after transfection.
- FIG. 3 The results of measuring the number of cells for CACO-2 are shown in FIG. 3, and the results of measuring the number of cells for SK-MEL-28 and A2058 are shown in FIG.
- FIG. 3 when GST- ⁇ siRNA alone was allowed to act on a colon cancer cell line (CACO-2 strain having a mutation in the BRAF gene), PLX4720 was allowed to act on the colon cancer cell line together with siControl. It was shown that, when these GST- ⁇ ⁇ ⁇ siRNA and PLX4720 were used in combination with these cell lines, the cell growth inhibitory effect was remarkable.
- FIG. 3 when GST- ⁇ siRNA alone was allowed to act on a colon cancer cell line (CACO-2 strain having a mutation in the BRAF gene), PLX4720 was allowed to act on the colon cancer cell line together with siControl. It was shown that, when these GST- ⁇ ⁇ ⁇ siRNA and PLX4720 were used in combination with these cell lines, the cell growth inhibitory effect was remarkable.
- FIG. 3 when these GST- ⁇
- Example 3 the cell growth inhibitory effect when a drug that suppresses GST- ⁇ is applied to a cell having a mutation in the BRAF gene and having resistance to a BRAF inhibitor (BRAF inhibitor resistant cell). It was investigated.
- the BRAF inhibitor resistant cells used in this example were prepared as follows. Melanoma cell line A375 used in Example 1 in DMEM medium containing 15% FBS and antibiotics supplemented with 1-5 ⁇ M PLX4720 (Selleck) for 1 month in an atmosphere containing 5% CO 2 at 37 ° C Incubated. A cell line that survived one month of incubation was used in this example as PLX4720 resistant A375 cells.
- PLX4720-resistant A375 cells were seeded on 100 mm tissue culture plastic dishes using DMEM medium containing 15% FBS without antibiotics so as to be 0.5 ⁇ 10 6 cells / 10 ml.
- Opti-MEM I Reduced Serum Medium GEBCO
- 600 pmol of GST- ⁇ siRNA GGGAGGCAAGACCUUCAUUTT, siRNA ID # 2385, Ambion (SEQ ID NO: 3)
- 35 ⁇ L of Lipofectamine RNAi MAX (Invitrogen) was diluted in 1 mL of Opti-MEM I Reduced Serum Medium (GIBCO) and mixed gently.
- the diluted GST- ⁇ siRNA and the diluted Lipofectamine RNAi MAX were gently mixed and then incubated at room temperature for 10 minutes. During this time, the medium was replaced with 10 mL of Opti-MEM I Reduced Serum Medium. After 10 minutes incubation, the complex of GST- ⁇ siRNA and Lipofectamine RNAi MAX was added to the cells and incubated at 37 ° C. in an atmosphere containing 5% CO 2 . After incubation for 5 hours, the medium was replaced with 10 mL of antibiotic-free DMEM medium containing 15% FBS.
- the collected cells were washed with cold PBS, followed by cold lysis buffer (1% NP-40, 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, complete Mini EDTA-free (Roche), PhosSTOP (Roche) was added, and the mixture was solubilized by ice cooling and incubation for 30 minutes. Centrifugation was performed at 4 ° C. and 15000 rpm for 15 minutes to obtain a cell extract. The obtained cell extract was subjected to protein quantification using Micro BCA Protein Assay Kit (Thermo SCIENTIFIC).
- the secondary antibody reaction was performed at room temperature for 1 hour using a horseradish peroxidase (HRP) -labeled rabbit antibody.
- Band signal detection was performed on X-ray film by chemiluminescence using ECL Western Blocking Detection Reagents (GE Healthcare). Washing between each operation was carried out 4 times with PBS-T for 5 minutes.
- melanoma cell lines that have acquired resistance to BRAF inhibitors are involved in the recurrence of melanoma. Therefore, in order to investigate whether GST- ⁇ promotes CRAF dependence of BRAF inhibitor-resistant melanoma, GST- ⁇ was knocked down with PLX4720-resistant A375. When cell proliferation was measured, a remarkable growth inhibitory effect was observed (FIG. 5). When GST- ⁇ knockdown was confirmed, GST- ⁇ expression was suppressed on the second and third days (FIG. 6).
- This example demonstrates that the growth of cells having a mutation in the BRAF gene and having resistance to a BRAF inhibitor (BRAF inhibitor-resistant cells) can be effectively suppressed. From this result, it is possible to expect an effect of preventing or reducing a disease caused by BRAF inhibitor resistant cells, for example, recurrence of melanoma.
Abstract
Description
〔実施例1〕
本実施例では、BRAF遺伝子に変異を有する細胞に対してGST-πを抑制する薬物を作用させたときの細胞増殖抑制効果を検討した。先ず、BRAF遺伝子に変異(V600E)を有するがん細胞として、大腸癌細胞株1種類(CACO-2)、メラノーマ細胞株4種類(A375、SK-MEL-28、A2058、Malme-3M)を37℃で5% CO2を含む大気下で培養した。使用した培地は、CACO-2はMEM+20%、FBS+0.1mM及びNEAAとし、A375はDMEM+15%及びFBSとし、SK-MEL-28はEMEM+10%及びFBSとし、A2058はDMEM+10%及びFBSとし、Malme-3MはIMDM+20%及びFBSとし、いずれも抗生物質を添加した。
本実施例では、BRAF遺伝子に変異を有する細胞に対してGST-πを抑制する薬物及びBRAF阻害剤を作用させたときの細胞増殖抑制効果を検討した。
本実施例では、BRAF遺伝子に変異を有する細胞であってBRAF阻害剤に耐性を有する細胞(BRAF阻害剤耐性細胞)に対してGST-πを抑制する薬物を作用させたときの細胞増殖抑制効果を検討した。
<細胞数測定>
本実施例で使用したBRAF阻害剤耐性細胞は以下のように作製した。実施例1で使用したメラノーマ細胞株A375を1~5μMのPLX4720(Selleck社)を添加した抗生物質と15% FBSを含むDMEM培地で、37℃で5% CO2を含む大気下で1ヵ月間インキュベートした。1ヵ月間のインキュベートの後に生存する細胞株をPLX4720耐性A375細胞として本実施例に使用した。
<GST-π発現確認>
上述のように、PLX4720耐性A375細胞に対してGST-π siRNAを作用させたときのGST-πの発現をウエスタンブロットにより確認した。すなわち、GST-π siRNAのトランスフェクション後の上記各時点において採取した細胞を用いてGST-πノックダウンのウエスタンブロット解析を行った。
<結果>
近年、BRAF阻害剤耐性を獲得したメラノーマ細胞株がメラノーマの再発に関与することが解っている。そこで、GST-πがBRAF阻害剤耐性メラノーマのCRAF依存性を促進しているかどうかを調べるために、PLX4720耐性A375でGST-πをノックダウンした。細胞増殖を測定したところ、顕著な増殖抑制効果が認められた(図5)。GST-πノックダウンを確認したところ、2日目と3日目でGST-π発現が抑制されていた(図6)。
Claims (12)
- GST-πを抑制する薬物を有効成分として含む、BRAF遺伝子に変異を有する細胞の細胞死誘導剤。
- GST-πを抑制する薬物を有効成分として含む、BRAF遺伝子に変異を有する細胞の細胞増殖抑制剤。
- 上記変異は、V600E変異であることを特徴とする請求項1又は2記載の剤。
- 上記BRAF遺伝子に変異を有する細胞は、BRAF阻害剤に対する耐性を有する細胞であることを特徴とする請求項1又は2記載の剤。
- 上記薬物が、RNAi分子、リボザイム、アンチセンス核酸、DNA/RNAキメラポリヌクレオチド及びこれらのうち少なくとも1種を発現するベクターからなる群から選択される物質であることを特徴とする請求項1又は2記載の剤。
- 上記BRAF遺伝子に変異を有する細胞が、GST-πを高発現するがん細胞であることを特徴とする請求項1又は2記載の剤。
- 請求項1乃至6のいずれか一項記載の剤を含む、BRAF遺伝子に変異を有する細胞の増殖異常に起因する疾患の治療用医薬組成物。
- 上記疾患ががんであることを特徴とする請求項7記載の医薬組成物。
- 上記がんはGST-πを高発現するがんであることを特徴とする請求項8記載の医薬組成物。
- 上記がんは大腸癌又はメラノーマであることを特徴とする請求項8記載の医薬組成物。
- GST-πを抑制する薬物を選択することを含む、BRAF遺伝子に変異を有する細胞の細胞死誘導剤及び/又は細胞増殖抑制剤のスクリーニング方法。
- がん細胞に対して被検物質を接触させる工程と、上記細胞におけるGST-πの発現量を測定する工程と、被検物質の非存在下において測定した場合と比較して、当該発現量が低下した場合に上記GST-πを抑制する薬物として選択する工程とを含む請求項11記載のスクリーニング方法。
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2982643A CA2982643A1 (en) | 2015-04-16 | 2016-04-15 | Cell death inducing agent for cells having braf gene mutation, growth suppressing agent for same cells and pharmaceutical composition for therapy of diseases caused by growth defect of same cells |
CN202310302851.0A CN116271056A (zh) | 2015-04-16 | 2016-04-15 | 针对具有braf基因突变的细胞的细胞死亡诱导试剂、该细胞的增殖抑制试剂及用于治疗由该细胞的增殖异常导致的疾病的医药组合物 |
EP16780131.5A EP3284481A4 (en) | 2015-04-16 | 2016-04-15 | Cell death inducing agent for cells having braf gene mutation, agent for inhibiting proliferation of said cells and pharmaceutical composition for treating patient suffering from effects of abnormal proliferation of said cells |
CN201680021988.7A CN107530433A (zh) | 2015-04-16 | 2016-04-15 | 针对具有braf基因突变的细胞的细胞死亡诱导试剂、该细胞的增殖抑制试剂及用于治疗由该细胞的增殖异常导致的疾病的医药组合物 |
AU2016249567A AU2016249567B2 (en) | 2015-04-16 | 2016-04-15 | Cell death inducing agent for cells having BRAF gene mutation, growth suppressing agent for same cells and pharmaceutical composition for therapy of diseases caused by growth defect of same cells |
US15/567,062 US10570396B2 (en) | 2015-04-16 | 2016-04-15 | Cell death inducing agent for cells having BRAF gene mutation, growth suppressing agent for same cells and pharmaceutical composition for therapy of diseases caused by growth defect of same cells |
RU2017139718A RU2760835C2 (ru) | 2015-04-16 | 2016-04-15 | Агент, индуцирующий клеточную гибель, для клеток, имеющих мутации гена braf, агент, подавляющий рост таких клеток, и фармацевтическая композиция для терапии заболеваний, вызванных дефектом роста таких клеток |
KR1020177031501A KR20170138453A (ko) | 2015-04-16 | 2016-04-15 | Braf 유전자 변이를 갖는 세포에 대한 세포사 유도제, 당해 세포의 증식 억제제 및 당해 세포의 증식 이상에서 기인하는 질환의 치료용 의약 조성물 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015-084286 | 2015-04-16 | ||
JP2015084286 | 2015-04-16 | ||
JP2016078710A JP6864990B2 (ja) | 2015-04-16 | 2016-04-11 | Braf遺伝子変異を有する細胞に対する細胞死誘導剤、当該細胞の増殖抑制剤及び当該細胞の増殖異常に起因する疾患の治療用医薬組成物 |
JP2016-078710 | 2016-04-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016167340A1 true WO2016167340A1 (ja) | 2016-10-20 |
Family
ID=57127072
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2016/062090 WO2016167340A1 (ja) | 2015-04-16 | 2016-04-15 | Braf遺伝子変異を有する細胞に対する細胞死誘導剤、当該細胞の増殖抑制剤及び当該細胞の増殖異常に起因する疾患の治療用医薬組成物 |
Country Status (3)
Country | Link |
---|---|
CN (1) | CN116271056A (ja) |
RU (1) | RU2760835C2 (ja) |
WO (1) | WO2016167340A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2798091C2 (ru) * | 2017-10-26 | 2023-06-15 | Ксиномик Фармасьютикалз, Инк. | Кристаллические соли ингибитора b-raf-киназы |
US11753409B2 (en) | 2017-10-26 | 2023-09-12 | Xynomic Pharmaceuticals, Inc. | Crystalline salts of a B-RAF kinase inhibitor |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012176282A1 (ja) * | 2011-06-21 | 2012-12-27 | 日東電工株式会社 | アポトーシス誘導剤 |
WO2014098210A1 (ja) * | 2012-12-20 | 2014-06-26 | 日東電工株式会社 | アポトーシス誘導剤 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201312155D0 (en) * | 2013-07-05 | 2013-08-21 | Ucl Business Plc | Therapeutic invention |
-
2016
- 2016-04-15 RU RU2017139718A patent/RU2760835C2/ru active
- 2016-04-15 WO PCT/JP2016/062090 patent/WO2016167340A1/ja active Application Filing
- 2016-04-15 CN CN202310302851.0A patent/CN116271056A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012176282A1 (ja) * | 2011-06-21 | 2012-12-27 | 日東電工株式会社 | アポトーシス誘導剤 |
WO2014098210A1 (ja) * | 2012-12-20 | 2014-06-26 | 日東電工株式会社 | アポトーシス誘導剤 |
Non-Patent Citations (3)
Title |
---|
LUCA, A.D. ET AL.: "A novel orally active water- soluble inhibitor of human glutathione transferase exerts a potent and selective antitumor activity against human melanoma xenografts", ONCOTARGET, vol. 6, no. 6, February 2015 (2015-02-01), pages 4126 - 4143, XP055321169, ISSN: 1949-2553 * |
TSAI, J. ET AL.: "Discovery of a selective inhibitor of oncogenic B-raf kinase with potent antimelanoma activity", PNAS, vol. 105, no. 8, 2008, pages 3041 - 3046, XP055003766, ISSN: 1091-6490 * |
TURLEY, C.K. ET AL.: "GSTP1 suppression induces apoptosis in melanoma cells independent of BRAF mutational status.", JOURNAL OF SURGICAL RESEARCH, vol. 172, no. 2, 2012, pages 229, XP055491483, ISSN: 0022-4804 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2798091C2 (ru) * | 2017-10-26 | 2023-06-15 | Ксиномик Фармасьютикалз, Инк. | Кристаллические соли ингибитора b-raf-киназы |
US11753409B2 (en) | 2017-10-26 | 2023-09-12 | Xynomic Pharmaceuticals, Inc. | Crystalline salts of a B-RAF kinase inhibitor |
Also Published As
Publication number | Publication date |
---|---|
RU2760835C2 (ru) | 2021-11-30 |
CN116271056A (zh) | 2023-06-23 |
RU2017139718A3 (ja) | 2019-10-02 |
RU2017139718A (ru) | 2019-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7471361B2 (ja) | Braf遺伝子変異を有する細胞に対する細胞死誘導剤、当該細胞の増殖抑制剤及び当該細胞の増殖異常に起因する疾患の治療用医薬組成物 | |
JP6340162B2 (ja) | アポトーシス誘導剤 | |
JP2017014185A (ja) | 細胞死誘導剤、細胞増殖抑制剤及び細胞の増殖異常に起因する疾患の治療用医薬組成物 | |
US10780107B2 (en) | Agent for inducing cell death, agent for suppressing cell proliferation, and pharmaceutical composition used for treatment of disease resulting from abnormal cell proliferation | |
JP6727765B2 (ja) | アポトーシス誘導剤 | |
WO2016167340A1 (ja) | Braf遺伝子変異を有する細胞に対する細胞死誘導剤、当該細胞の増殖抑制剤及び当該細胞の増殖異常に起因する疾患の治療用医薬組成物 | |
JP2021183618A (ja) | 細胞増殖抑制剤及びそれを含むがんの治療若しくは予防用医薬組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16780131 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2982643 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15567062 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20177031501 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2016249567 Country of ref document: AU Date of ref document: 20160415 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2017139718 Country of ref document: RU |